We are planning a first in man clinical .trial with topical NFX-179 in 2019. This trial will evaluate multiple doses of NFX-179 and a matching placebo in patients with cutaneous neurofibromas, epidermal nevi, and nevus sebaceous. Further details will be available shortly.

Current Investors

Address: NFlection Therapeutics, Inc., One Broadway, 14th Floor, Cambridge, MA 02142

Email: info@nflectionrx.com

logo 4png.png